Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Percheron Therapeutics Limited
ATHJFCurrent price
0.057 USD
0 USD (0.00%)
Last closed
0.081 AUD
Company
www.antisense.com.au
ISIN
AU000000ANP4
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
AU
Capitalization
84 195 274 AUD
Yield for 12 month
+38.60 %
1Y
3Y
5Y
10Y
15Y
ATHJF
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Address: L30, Collins Place, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.32 AUDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+385 911 AUD
Current Quarter
+544 632 AUD
Last Quarter
+544 632 AUD
Current Year
–
Last Year
–
Current Quarter
+537 706 AUD
Last Quarter
+537 706 AUD
Key Figures ATHJF
1 year
3 years
5 years
10 years
EBITDA
-11 930 983 AUD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-54.4 %
PEG Ratio
–
Return On Equity TTM
-123.27 %
Wall Street Target Price
0.32 AUD
Revenue TTM
2 975 815 AUD
Book Value
0.01 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
20.2 %
Dividend Yield
–
Gross Profit TTM
1 550 794 AUD
Earnings per share
-0.01 AUD
Diluted Eps TTM
-0.01 AUD
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATHJF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATHJF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
50:49
Payout Ratio
–
Last Split Date
10.04.2018
Dividend Date
–
Stock Valuation ATHJF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
347.0025
Price Sales TTM
27.9439
Enterprise Value EBITDA
-4.4641
Price Book MRQ
8.9691
Financials ATHJF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATHJF
For 52 weeks
0.052 AUD
0.14 AUD
50 Day MA
0.093 AUD
Shares Short Prior Month
–
200 Day MA
0.081 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart